Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance

4 Less than a minute

Astellas Pharma press release (OTCPK:ALPMF): FY Non-GAAP EPS of ¥84.19.
Revenue of ¥1603.67B (+5.6% Y/Y).
Net cash flows from operating activities in FY2023 decreased by ¥155.3 billion year-on-year to ¥172.5 billion.
As a result, cash and cash equivalents totaled ¥335.7 billion as of March 31, 2024, a decrease of ¥41.2 billion compared to the end of the previous fiscal year.
The Company’s business forecasts for FY2024 are presented on a core basis and full basis. The consolidated full-year business forecasts (core basis) are shown below. (Millions of yen) FY2024 Revenue ¥1,650,000M (+2.9%); Basic core earnings per share ¥ 103.73 (-16.7%).